Compositions and methods for viral sensitization
US-2024360115-A1 · Oct 31, 2024 · US
MEK inhibitors and methods of their use
US11597699B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11597699-B2 |
| Application number | US-202016853043-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 20, 2020 |
| Priority date | Oct 7, 2005 |
| Publication date | Mar 7, 2023 |
| Grant date | Mar 7, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.
First claim
Opening claim text (preview).
We claim: 1. A method of arresting the development of or causing the regression of malignant fibrous histiocytoma, comprising administering to a patient in need thereof a therapeutically effective amount of 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2S)-piperidin-2-yl]azetidin-3-ol or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
containing three or more hetero rings · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11597699B2 cover?
- Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.
- Who is the assignee on this patent?
- Exelixis Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D403/06. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).